NASDAQ:CLRB
Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc. reported net income of −$21.8M in fiscal 2025. Free cash flow was −$23.1M, and the diluted share count rose 110.7%.Summary generated from Cellectar Biosciences, Inc.'s SEC filings. Latest annual report filed Mar 4, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−190.9%
Debt / equityn/a
Free cash flow−$23.1M
FCF marginn/a
Share count change+110.7%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −24 | −29 | −39 | −52 | −23 |
| Net income | −24 | −32 | −43 | −45 | −22 |
| Free cash flow | −23 | −25 | −33 | −48 | −23 |
Recent filings
- 8-KResults of operations and financial condition
Aug 13, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 8-KDirector or officer change
Jul 10, 2026 - 4Insider transaction report
Jul 8, 2026 - 4Insider transaction report
Jul 8, 2026 - DEF 14AProxy statement
May 28, 2026 - S-1Registration statement
May 19, 2026 - 8-KDirector or officer change
May 18, 2026